A Seattle biotechnology company, Immune Design, working on immune-based therapies to fight cancer, filed documents with the Securities and Exchange Commission to go public.
The biotech, on Eastlake Avenue East, said it wants to raise $60 million to finish the phase 1 clinical trials and to support continued development, including into phase 2 clinical trials.
The company's primary research and focus is on targeting tumors and killing them off through the body's immune system. The treatment is done through a series of injections on patients with melanoma, non-small cell lung cancer, breast cancer, ovarian cancer, sarcoma or Merkel cell carcinoma.
Immune Design has three clinic trials ongoing. The most recent, which began in
Most Popular Stories
- Bently Creates Alabama Small Business Commission
- Is Alibaba's IPO Price a Fairytale?
- Kardashian: Kanye Never Told Fan in Wheelchair to Stand Up
- Los Angeles Angels Clinch Playoff Spot
- U.S. Tobacco Growers Lose Last of Price Supports
- CalPERS Pulls Out of Hedge Funds
- U.S. Producer Prices Held Steady in August
- Sanctions Push Russian Ruble to Historic Low
- Scottish Leaders Scramble for Votes on Independence
- When to Say No to Investors, Yes to Mentors